Elizabeth “Blair” Solow, MD, MSc, and Angus Worthing, MD, FACP, FACR, described the top political issues affecting rheumatology now and how ACR members can work toward practices and policies that help us better care for patients.
Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
New Findings for Polymyalgia Rheumatica & Osteoarthritis
The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.
Considering Benzbromarone as First-Line Therapy for Gout
In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.
Challenges in Psoriatic Arthritis
PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but…
Duke Researchers Create a Type 1, Type 2 Lupus Disease Model
A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to categorize two main groups of symptoms into type 1, typically…
New ARP President Kori Dewing, ARNP, DNP, Traces Her Journey to This Point & Possibilities Moving Forward
Kori Dewing, ARNP, DNP, has been working in healthcare since high school. As she begins her term as president of the ARP, she is building on nearly two decades of volunteer experience with the ARP and ACR to continue supporting rheumatology professionals and advancing the College’s values of inclusion, collaboration and community.
Advocacy Involvement ‘An Antidote to Burnout,’ Says New Government Affairs Chair Christina Downey, MD
The new chair of the ACR’s Government Affairs Committee, Dr. Downey says physicians play a vital role in helping policymakers understand how policies and laws affect patients and the practice of rheumatology.
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
PHILADELPHIA—“At age 12, I was diagnosed with psoriasis (PsO), followed by a diagnosis of psoriatic arthritis (PsA) at age 30,” said Ashley Krivohlavek of Oklahoma City in a poster presentation at ACR Convergence 2022. “I’m now 38.” Ms. Krivohlavek’s Story In 2020, I had been on an infused biologic for 18 months, but my…
Big Utilization Management Reform Wins in Pennsylvania, Massachusetts
Prior authorization and step therapy reform bills recently enacted in Pennsylvania and Massachusetts offer case studies into how substantive policy change can take persistence, patience and a bipartisan approach to achieve success.
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 816
- Next Page »